Tests a Ciplukan skin cream for psoriasis plaques
Tests a Ciplukan cream against steroid cream in adults with psoriasis skin patches.
Plain-language title generated from the registry record
Registry title: The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
Key facts
- Where
- Bandung, IndonesiaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with psoriasis vulgaris, a long-term inflammatory skin disease, to test a skin cream made with Ciplukan.
- Age
- 18 to 60 years
- Sex
- All sexes can join.
- Disease stage
- Psoriasis vulgaris, diagnosed from medical history, a physical exam and a severity score (PASI).
- Earlier treatment
- Must have stopped systemic therapy or phototherapy for psoriasis more than 30 days ago, and other skin treatments (except moisturizers) more than 14 days ago.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Currently on systemic therapy for psoriasis vulgaris
- Stopped systemic therapy or phototherapy 30 days ago or less
- Stopped topical treatment (other than moisturizers) 14 days ago or less
- Psoriasis patches on trauma-prone areas, palms, soles, face or skin folds
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06887322, who can take part
Where in Indonesia
- Hasan sadikin general hospitalBandung, IndonesiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universitas Padjadjaran
- Trial code
- NCT06887322
- Record updated
- 1 April 2025
- Original description
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and are produced from the NF-κB signaling pathway play a role in the pathogenesis of psoriasis vulgaris. Topical corticosteroids are the first-line therapy for all severity levels of psoriasis vulgaris, possessing immunosuppressive, anti-inflammatory, and antimitotic effects. However, long-term use can lead to side effects such as atrophy, striae, telangiectasia, hypopigmentation, acneiform eruptions, perioral dermatitis, and hypertrichosis.Read full original descriptionShow less
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Modified Psoriasis Area and Severity Index, Thickness, and Inflammation of Psoriasis Vulgaris Lesions
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and are produced from the NF-κB signaling pathway play a role in the pathogenesis of psoriasis vulgaris. Topical corticosteroids are the first-line therapy for all severity levels of psoriasis vulgaris, possessing immunosuppressive, anti-inflammatory, and antimitotic effects. However, long-term use can lead to side effects such as atrophy, striae, telangiectasia, hypopigmentation, acneiform eruptions, perioral dermatitis, and hypertrichosis.
Inclusion: Age 18 - 60 years; Diagnosed with psoriasis vulgaris based on medical history, physical examination, and severity assessment using the PASI score.
Exclusion: Patients currently undergoing systemic therapy for psoriasis vulgaris; Patients who have not discontinued systemic therapy/phototherapy for psoriasis vulgaris ≤ 30 days; Patients with psoriasis vulgaris who have not discontinued topical therapy (other than moisturizers) ≤ 14 days; Pregnant or breastfeeding women; Psoriasis vulgaris lesions located in trauma-prone areas, palms, soles, face, and skin folds.